Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

By The Northwire Desk — AI Analysis Jun 02, 2026 · 07:30 OPTI · 7.9 Optimi Health Corp.
Executive Summary
  • Optimi Health Corp. completed a GMP production run of its 5mg psilocybin finished drug product.
  • The company operates a fully vertically integrated manufacturing pipeline covering biomass cultivation, API extraction, encapsulation, and packaging under a Health Canada Drug Establishment Licence (DEL).
  • Finished capsules are commercially prescribed in Australia for treatment-resistant depression (TRD) under the Authorized Prescriber Scheme.
  • An updated bottling configuration has been rolled out to improve usability for prescribers and patients.
  • Remaining inventory from the production run is allocated to support upcoming clinical trials in the United States and Europe.
  • The facility features a Level 8 vault compliant with institutional security standards, authorized to store up to 20kg of psilocybin and ~2,000kg of biomass.
  • The company also supplies MDMA and psilocybin drug products to regulated international markets for patient access and clinical research.
Material Impact
  • The June 2 announcement is a direct follow-up to the May 26 milestone regarding the highest-purity natural psilocybin extract (~6%) and the May 29 regulatory expansion in Australia.
  • It confirms the operationalization of the company's vertically integrated manufacturing thesis, validating that the GMP facility can produce commercial-grade finished products at scale.
  • The allocation of inventory to US and European clinical trials demonstrates progress in diversifying revenue streams beyond the Australian market.
  • However, the news is incremental. It does not introduce new contracts, revenue jumps, or regulatory approvals that would materially alter the company's valuation. It is a routine execution update that confirms management's stated roadmap.
OPTI · Price
Company Overview
  • Optimi Health Corp. is a vertically integrated psychedelic pharmaceutical company focused on the manufacturing and supply of GMP-grade psilocybin and MDMA.
  • Flagship Project: 5mg naturally derived psilocybin capsules for treatment-resistant depression (TRD) and 40mg/60mg MDMA capsules for PTSD.
  • The company operates two 10,000 sq ft GMP-compliant facilities in British Columbia, Canada, holding a Health Canada DEL.
  • Commercial operations are currently anchored in Australia under the TGA's Authorized Prescriber Scheme, with expansion plans into the US and Europe.
Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory May 26, 2026 · 07:01

Optimi Health Manufacturing Milestone Validates Capital Raise But Nasdaq Uplifting Remains Primary Valuation Driver

Production / Operations